Please upgrade your browser.
Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial to evaluate whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient's relative.
Cancer experts said the research, carried out by The Sunday Telegraph, exposed a "grotesque lottery" in which life-and-death decisions were routinely being made by bureaucrats who were "unelected, unaccountable and unqualified" to make the rulings.
Event to honor Kyle Blakeman, who lost his battle at the age of 13 to Renal Medullary Carcinoma.
At a personal level, most Americans do not think the current reform legislation will improve their health care or lower their costs.
Gail Balding, 62, died last November to kidney cancer following a prolonged fight to get Sutent, a life-prolonging drug. She was refused the drug three times after appealing.
The drugs include infliximab and etanercept, which are used for the treatment of juvenile rheumatoid arthritis (JRA), Crohn's disease and other inflammatory diseases.
The European Commission has approved everolimus (Afinitor) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
Malignancies such as leiomyosarcoma, hepatic malignancies, and renal cell carcinoma were also reported.
Interim tivozanib Phase 2 data presented by AVEO at the 2009 Genitourinary Symposium (ASCO GU) in February 2009 showed a disease control rate of greater than 90 percent, plus excellent tolerability, in patients with advanced renal cell carcinoma (RCC).
There is a second world of drug research, a world in which patents do not exist and for-profit research is permanently moribund. Its history should stop reformers in their tracks.
|Powered by NeonCRM|